In reality, cannabis’ full range of beneficial medicinal actions can’t be realized with just CBD. In fact CBD “isolated” medicines don’t even come close to accomplishing what whole flower preparations can – or even what CBD plus THC can do by themselves in isolation (as one pharmaceutical approved in many countries – but not the US – tries to do).
While advanced research gears up, many of cannabis’ hundreds of compounds are starting to be studied for their involvement in the “entourage effect” where many different compounds are likely part of the herb’s synergistic therapeutic effects.
Meet CBC: cannabichromene.
“Discovered over 50 years ago, CBC is considered one of the ‘big six’ cannabinoids prominent in medical research. It doesn’t get as much attention, but CBC’s benefits are extremely promising.
CBC has the same origins as both THC and CBD do in that they all stem from cannabigerolic acid (CBGA).
CBC is non-psychoactive, so it doesn’t produce a euphoric high like THC. The reason it is non-psychoactive is because it binds poorly to CB1 cannabinoid receptors in the brain.
But CBC does bind with other receptors in the body, such as the vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1), both of which are linked to pain perception. When CBC activates these receptors, increased levels of the body’s natural endocannabinoids like anandamide are released.
CBC’s medicinal potential promises to be broad… …The article goes into a fair amount of detail about roles it may play in the treatment of areas as diverse as pain and inflammation, neuroprotective effects and possibly in cancer treatment, among others.
This is info we haven’t blogged before, FYI, and highly recommended for helping flesh out the whole picture of medical cannabis.
#MMJ #Research #Cannabinoids #CBC #UTpol #TRUCE
See full article – “What Is CBC and What Are the Benefits of This Cannabinoid? | Leafly”